Cargando…

Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial

INTRODUCTION: Evolocumab, a fully human proprotein convertase/subtilisin kexin type 9 inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus and hyperlipidemia and mixed dyslipidemia. This 12-week study evaluated the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Hong, Li, Weimin, Huang, Zhouqing, Han, Yajun, Huang, Xuecheng, Li, Dongye, Xing, Xiaochun, Monsalvo, Maria Laura, Wu, You, Mao, Jackie, Xin, Lily, Chen, Jiyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942644/ https://www.ncbi.nlm.nih.gov/pubmed/36802321 http://dx.doi.org/10.1007/s40119-023-00304-x

Ejemplares similares

The Traditional Chinese Medicine Hua Tuo Zai Zao Wan Alleviates Atherosclerosis by Deactivation of Inflammatory Macrophages
por: Yu, Zhihua, et al.
Publicado: (2022)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON
por: Lorenzatti, Alberto J., et al.
Publicado: (2021)

Electroacupuncture at Hua Tuo Jia Ji Acupoints Reduced Neuropathic Pain and Increased GABA(A) Receptors in Rat Spinal Cord
por: Jiang, Siao-Wei, et al.
Publicado: (2018)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Protocol for Home-Based Solution for Remote Atrial Fibrillation Screening to Prevent Recurrence Stroke (HUA-TUO AF Trial): a randomised controlled trial
por: Wong, Chun Ka, et al.
Publicado: (2022)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
por: Huang, Chin-Chou, et al.
Publicado: (2019)

Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
por: Sasaki, Jun
Publicado: (2010)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?
por: Hang, Shyann, et al.
Publicado: (2021)

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
por: Rosenson, Robert S., et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
por: Alghamdi, Ahmed, et al.
Publicado: (2021)

Cernin jättikiihdytin ei tuo maailmanloppua keskiviikkona
Publicado: (2008)

A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
por: Ge, Xiaoyue, et al.
Publicado: (2021)

Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial
por: Lorenzatti, Alberto J., et al.
Publicado: (2019)

Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
por: Kuchimanchi, Mita, et al.
Publicado: (2018)

The Draupadi of dyslipidemia: Familial hypercholesterolemia
por: Kalra, Sanjay, et al.
Publicado: (2016)

Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes
por: Blom, Dirk J., et al.
Publicado: (2020)

Short-term evolocumab-induced tendon xanthomas regression in an elderly patient with homozygous familial hypercholesterolemia
por: Cicero, Arrigo F. G., et al.
Publicado: (2022)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Viljoen, Adie, et al.
Publicado: (2010)

Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Hussein, Ayman A, et al.
Publicado: (2010)

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2009)

An Untargeted Lipidomic Analysis Reveals Depletion of Several Phospholipid Classes in Patients with Familial Hypercholesterolemia on Treatment with Evolocumab
por: Anesi, Andrea, et al.
Publicado: (2021)

Microbial diversity and component variation in Xiaguan Tuo Tea during pile fermentation
por: Li, Haizhou, et al.
Publicado: (2018)

Xin hua jing /
Publicado: (1982)

Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab
por: Tanaka, Akihito, et al.
Publicado: (2017)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019
por: Bilitou, Aikaterini, et al.
Publicado: (2022)

TICSA TruSecure ICSA certified security associate: exam TUO-001 : training guide
por: Chapple, Mike, et al.
Publicado: (2003)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
por: Leucker, Thorsten M., et al.
Publicado: (2020)

Attribution Analysis of Runoff Change in Min-Tuo River Basin based on SWAT model simulations, China
por: Hu, Jian, et al.
Publicado: (2020)

Microbial quality and antibiotic sensitivity of bacterial isolates in “Tuo‐Zaafi” vended in the central business district of tamale
por: Abas, Rufina, et al.
Publicado: (2019)

Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia
por: Fukami, Hirotaka, et al.
Publicado: (2021)

Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
por: Toth, Peter P., et al.
Publicado: (2020)

First person – Jiang-Hua Liu
Publicado: (2020)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

Maculopapular Exanthema After the Second Dose of Evolocumab
por: Ghernautan, Victoria, et al.
Publicado: (2021)

Prevalence of dyslipidemia and hypercholesterolemia awareness: results from the Lookup 7+ online project
por: Martone, Anna Maria, et al.
Publicado: (2022)

Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre‐specified analysis of the Chinese population from the BERSON clinical trial
por: Chen, Yundai, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5eq6tm234lduulaj9i2kd9qc1f